ES2196181T3 - Derivados de purina y proceso para su preparacion. - Google Patents

Derivados de purina y proceso para su preparacion.

Info

Publication number
ES2196181T3
ES2196181T3 ES96934774T ES96934774T ES2196181T3 ES 2196181 T3 ES2196181 T3 ES 2196181T3 ES 96934774 T ES96934774 T ES 96934774T ES 96934774 T ES96934774 T ES 96934774T ES 2196181 T3 ES2196181 T3 ES 2196181T3
Authority
ES
Spain
Prior art keywords
preparation
purine derivatives
diseases
quinasa
lina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96934774T
Other languages
English (en)
Inventor
Jurg Zimmermann
Hans-Georg Capraro
Patricia Imbach
Pascal Furet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2196181T3 publication Critical patent/ES2196181T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBEN DERIVADOS DE LA 2 - AMINO - 6 - ANILINO - PURINA DE FORMULA (1) EN LA CUAL LOS SIMBOLOS SE DEFINEN EN LA REIVINDICACION 1. ESTOS COMPUESTOS INHIBEN LA P34 CDC2 /CIC LINA B CDC13 - QUINASA Y SE PUEDEN UTILIZAR PARA EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS, COMO POR EJEMPLO ENFERMEDADES TUMORALES.
ES96934774T 1995-11-01 1996-10-22 Derivados de purina y proceso para su preparacion. Expired - Lifetime ES2196181T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH309495 1995-11-01
CH221396 1996-09-10

Publications (1)

Publication Number Publication Date
ES2196181T3 true ES2196181T3 (es) 2003-12-16

Family

ID=25689809

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96934774T Expired - Lifetime ES2196181T3 (es) 1995-11-01 1996-10-22 Derivados de purina y proceso para su preparacion.

Country Status (13)

Country Link
US (1) US7091346B1 (es)
EP (1) EP0874846B1 (es)
JP (2) JP4004066B2 (es)
CN (1) CN1066147C (es)
AR (1) AR004134A1 (es)
AT (1) ATE236161T1 (es)
AU (1) AU7296896A (es)
BR (1) BR9611157A (es)
CA (1) CA2234609C (es)
DE (1) DE69627195T2 (es)
ES (1) ES2196181T3 (es)
PT (1) PT874846E (es)
WO (1) WO1997016452A1 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US6794390B2 (en) * 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US6573044B1 (en) 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
US6255485B1 (en) 1997-08-07 2001-07-03 The Regents Of The University Of California Purine inhibitors of protein kinases, G proteins and polymerases
US6569878B1 (en) 1997-10-27 2003-05-27 Agouron Pharmaceuticals Inc. Substituted 4-amino-thiazol-2-yl compounds as cyclin-dependent kinase inhibitors
AU1631699A (en) * 1997-12-18 1999-07-05 E.I. Du Pont De Nemours And Company Cyclohexylamine arthropodicides and fungicides
US6642231B2 (en) * 1998-02-26 2003-11-04 Aventis Pharmaceuticals Inc. 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
KR100568657B1 (ko) * 1998-02-26 2006-04-07 아벤티스 파마슈티칼스 인크 6,9-이치환 2-[트랜스-(4-아미노시클로헥실)아미노]퓨린
WO1999043676A2 (en) * 1998-02-26 1999-09-02 Aventis Pharmaceuticals Inc. 6,9-disubstituted 2-[trans-(4- aminocyclohexyl) amino]purines
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
US20030187261A1 (en) * 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
AU2001252562A1 (en) * 2000-04-28 2001-11-12 Toshiharu Suzuki Medicinal compositions for suppressing beta-amyloid production
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
WO2003002565A1 (en) * 2001-06-27 2003-01-09 Cyclacel Limited 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders
CZ294535B6 (cs) * 2001-08-02 2005-01-12 Ústav Experimentální Botaniky Avčr Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
CN1523991A (zh) 2001-08-10 2004-08-25 ��˹��ŵ�� 单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途
CA2463563A1 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219052D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
US7151104B2 (en) 2002-09-19 2006-12-19 Schering Corporation Pyrazolopyridines as cyclin dependent kinase inhibitors
WO2004035132A2 (en) * 2002-10-15 2004-04-29 Irm Llc Compositions and methods for inducing osteogenesis
WO2004087056A2 (en) * 2003-03-28 2004-10-14 Scios Inc. BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
WO2007070872A1 (en) * 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
ME00811B (me) * 2006-12-08 2012-03-20 Novartis Ag JEDINJENJA l KOMPOZICIJE KAO INHIBITORI PROTEIN KINAZE
KR101364277B1 (ko) 2006-12-08 2014-02-21 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
CA2682019C (en) * 2007-03-28 2016-08-09 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
JP2010522722A (ja) * 2007-03-28 2010-07-08 ノイロサーチ アクティーゼルスカブ プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
CZ302225B6 (cs) * 2007-07-04 2010-12-29 Univerzita Palackého v Olomouci Substituované 6-anilinopurinové deriváty jako inhibitory cytokinin oxidasy a prípravky obsahující tyto slouceniny
KR101238585B1 (ko) * 2008-04-07 2013-02-28 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물
WO2010034707A1 (en) 2008-09-26 2010-04-01 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
US20110237607A1 (en) * 2008-09-26 2011-09-29 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
CA2829219C (en) 2011-03-09 2021-03-16 Richard G. Pestell Prostate cancer cell lines, gene signatures and uses thereof
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
US9453836B2 (en) 2012-05-14 2016-09-27 Richard G. Pestell Use of modulators of CCR5 in the treatment of cancer and cancer metastasis
AU2013283488A1 (en) 2012-06-26 2015-01-15 Saniona Aps A phenyl triazole derivative and its use for modulating the GABAA receptor complex
CN105283206B (zh) * 2013-03-27 2019-11-08 财团法人峨山社会福祉财团 包含p34的表达抑制剂或活性抑制剂作为有效成分的用于治疗或转移抑制癌的组合物
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
CN108064274A (zh) 2014-07-30 2018-05-22 耶达研究及发展有限公司 用于培养多能干细胞的培养基
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2016243529B2 (en) * 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN114149432B (zh) * 2016-09-30 2024-07-05 斯坦福国际研究院 用于癌症治疗的双重clk/cdk1抑制剂
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
WO2020152686A1 (en) 2019-01-23 2020-07-30 Yeda Research And Development Co. Ltd. Culture media for pluripotent stem cells
CN120289460A (zh) * 2024-01-09 2025-07-11 中国科学院合肥物质科学研究院 含有嘌呤环的化合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3529497A1 (de) 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
KR910700253A (ko) 1989-01-31 1991-03-14 로버트 제이, 바란 N_6-치환-9-메틸아데닌: 신규한 부류의 아데노신 수용체 길항질
ATE178335T1 (de) * 1992-01-06 1999-04-15 Wellcome Found Therapeutische nukleoside der 2',3'-dideoxy-3'- fluor -purin reihe
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US5753635A (en) 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
CA2463563A1 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
WO2004035132A2 (en) * 2002-10-15 2004-04-29 Irm Llc Compositions and methods for inducing osteogenesis

Also Published As

Publication number Publication date
JPH11514336A (ja) 1999-12-07
CA2234609C (en) 2006-11-28
EP0874846A1 (en) 1998-11-04
CN1066147C (zh) 2001-05-23
AU7296896A (en) 1997-05-22
BR9611157A (pt) 1999-03-30
HK1016580A1 (en) 1999-11-05
DE69627195T2 (de) 2004-01-29
AR004134A1 (es) 1998-09-30
ATE236161T1 (de) 2003-04-15
EP0874846B1 (en) 2003-04-02
CA2234609A1 (en) 1997-05-09
PT874846E (pt) 2003-08-29
JP4004066B2 (ja) 2007-11-07
WO1997016452A1 (en) 1997-05-09
CN1202896A (zh) 1998-12-23
US7091346B1 (en) 2006-08-15
DE69627195D1 (de) 2003-05-08
JP2007231023A (ja) 2007-09-13

Similar Documents

Publication Publication Date Title
ES2196181T3 (es) Derivados de purina y proceso para su preparacion.
DE69912606D1 (de) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivate
AP2000002016A0 (en) 2-(Purin-9-yl) Tetrahydrofuran-3,4-diol derivatives.
YU44900A (sh) Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
YU29099A (sh) Derivati 2-(purin-9-il)-tetrahidrofuran-3,4-diola
ES2184705T3 (es) 4-oxo-4,7-dihidro-tieno(2,3-b)piridina-5-carboxamidas como agentes antivirales.
AP2000002013A0 (en) 2-(Purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives.
AP2000001881A0 (en) 2-(Purine-9-YL)-tetrahydrofuran-3,4 4-diol derivatives.
YU21401A (sh) Tetrahidropiridoetri
AU551324B2 (en) Phosphoramidite derivatives of nucleotides and their use in preparation of oligonucleotides
GB9903762D0 (en) Organic compounds
ES2171039T3 (es) Producto que comprende al menos un rna bicatenario en asociacion con al menos un interferon para el tratamiento de la hepatitis viral.
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
MXPA01008346A (es) Compuestos quimicos.
AU1044500A (en) Imidazonaphthyridines
PT971922E (pt) Compostos de tetra-hidropirido
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
SE9604582D0 (sv) Novel compounds
IT1293777B1 (it) Processo per la preparazione di tetraazamacrocicli
ID27440A (id) Proses untuk menyiapkan penengah-penengah
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
ITMI911877A1 (it) Enzimi fibrinolitici ammidati e loro precursori, e processi per la loro preparazione.
TW377353B (en) Purine derivatives and process for their preparation
DZ3260A1 (fr) PROCEDE DE PREPARATION DE 1,4]DIAZEPINO 6,7,1- i hi /i ]INDOL-4-ONES SUBSTITUEES